Capsugel, a global leader in delivering high-quality, innovative dosage forms and solutions announced major expansion of Pharmaceutical Product Development and Manufacturing Capabilities at its Edinburgh Facility.
The company will more than double the size of its Edinburgh facility by adding 40,000 square feet of space. The expansion will enable Capsugel’s Dosage Form Solutions business unit to both increase its liquid- and semi-solid-fill hard capsule manufacturing capacity for drug products containing high-potency active pharmaceutical ingredients (HPAPIs) and further diversify its technology platforms offered at the facility. These enhanced capabilities will help Capsugel’s pharmaceutical customers bring a greater range of new products to market more quickly.
The first phase of the expansion includes new analytical, formulation and quality laboratories designed to address customers’ bioavailability, HPAPI and other formulation challenges. The second phase, which is scheduled to begin later in 2015, will significantly expand commercial manufacturing capacity for the site’s existing technologies and bring the company’s other formulation and development technologies, including spray dried dispersion (SDD), to this location. Similar to Capsugel’s SDD center of excellence at its facility in Bend, Ore., the company’s SDD offering in Europe will eventually include development through commercial-scale capabilities.
Over the past two years, the Edinburgh facility has experienced approximately 40 percent growth in its development services business, while also establishing a strong commercial manufacturing pipeline – including eight late-stage projects currently in process.
|Type||Expansion of Pharmaceutical Product Development and Manufacturing Capabilities|
|Expansion Area||40,000 square feet|